Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isodiol International Inc ISOLF

Healthcare Drug Manufacturers - Specialty & Generic Cannabis
Isodiol International Inc is a manufacturer and developer of phytoceutical consumer products using pharmaceutical and nutraceutical grade phytochemical compounds. It generates revenue from the sale of nutritional health products derived from hemp. Geographically, it derives a majority of revenue from the United States and also has a presence in Canada. Its product categories include Tinctures; Capsules; Topicals; Vape; Oral Spray; Skincare; and others.


GREY:ISOLF - Post by User

Isodiol International Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by denvermckeeon May 12, 2018 8:42am
97 Views
Post# 28022019

News

NewsISODIOL INTERNATIONAL INC. INTENDS LEGAL CLAIM AGAINST COMPASS CANNABIS CLINIC (10330698 CANADA LTD.) FOR REPUDIATION OF DEFINITIVE AGREEMENT May 11, 2018 - Vancouver, BC – Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global CBD innovator specializing in the development of pharmaceutical, health, and wellness products announces that the Company intends to bring a legal claim against Compass Cannabis Clinic (“Compass”) for repudiation of the Definitive Agreement to acquire 19.9% equity in Compass, which had been previously announced on April 19, 2018. The Company seeks return of $2 million plus damages against Compass and its President Dave Martyn.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities